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EFFECT OF COMPLICATIONS ON HEALTH RELATED
QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED
DIABETIC PATINETS
Brodszky V1, Péntek M2, Majer I1, Karpati K1, Lepp-Gazdag A1,
Jelics N1, Gulácsi L1
1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc
County Hospital, Kistarcsa, Hungary
OBJECTIVES: The main goal of the study is to assess the health
related quality of life of Hungarian insulin treated patients in
order to offer country-speciﬁc data for cost-utility analysis. Also
to study the impact of diabetic complications on utility loss.
METHODS: In 2004 a multicenter cross-sectional questionnaire
survey was conducted among 480 insulin treated diabetic
patients in Hungary. Validated Hungarian version of the EQ-5D
questionnaire was used to assess health status. RESULTS:
Patients main characteristics were: women 56%, type 1 diabetes
58%, mean age 53 years, disease duration 18.6 years. Average
EQ-5D score was 0.7661, in subgroups of patients without, with
macrovascular, with microvascular and with both complications
were 0.84 (SD 0.23), 0.65 (SD 0.33), 0.70 (SD 0.30) and 0.61
(SD 0.34), respectively. Categorizing patients by type of diabetes,
EQ-5D scores similarly were 0.84 (SD 0.20), 0.77 (SD 0.16),
0.77 (SD 0.24), 0.78 (SD 0.25) in Type 1, and 0.72 (SD 0.3),
0,64 (SD 0.34), 0.67 (SD 0.32), 0.60 (SD 0.35) in Type 2.
Average EQ-5D of patients with nephropathy was 0.66 (SD
0.35), with retinopathy was 0.70 (SD 0,30) and with neuropa-
thy was 0.61 (SD 0.34). In absence of complications, the rate of
patients reporting problem in mobility, self-care, everyday activ-
ities, pain or anxiety were 18%, 4%, 14%, 33%, and 32%. Con-
trarily, these rates were 68%, 28%, 44%, 70%, and 56% in the
presence of both micro- and macrovascular disorders. CON-
CLUSIONS: Both microvascular and macrovascular complica-
tions has negative impact on health related quality of life in
insulin-dependent diabetic population in Hungary. Neuropathy
has the most negative effect. Complications in type 2 diabetes
induce lower EQ-5D scores than in type 1. Mobility dimension
of EQ-5D is the most affected by diabetic complications.
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PRIMARY CARE IN SPAIN
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OBJECTIVES: This study describes the health related quality of
life (HRQoL) of type 2 diabetic patients in Spain and explores
predictors of patients’ and physicians’ ratings of patients’
HRQoL. METHODS: Multicenter, naturalistic study of type 2
diabetes patients with a diagnosis longer than one year. Patients
were consecutively included in the study among those attending
any of the selected 30 Primary Care Centers distributed through-
out Spain Sociodemographic and clinical variables were col-
lected. Patients ﬁlled out the EuroQoL-5D questionnaire
(EQ-5D) and physicians ﬁlled out the EQ-5D proxy version.
Data analysis included two lineal regression models to evaluate
patients’ and physicians’ drivers of perceived HRQoL.
RESULTS: A totla of 294 patients were included in the study.
The mean age of the study participants was 67.5 and the mean
duration of diabetes was 9.9 years. The mean EQ-5D index score
was 0.71 (0.26) for patients’ self-measurement and 0.75 (0.23)
for physicians’ proxy measurement of patients’ HRQoL. For
both groups, pain/discomfort was the dimension with the highest
reported problems (>57%). Overall, there was good agreement
in the 5 EQ-5D dimensions between patients’ and physicians’
responses (weighted Kappa = 0.67–0.72), with only
anxiety/depression showing moderate agreement (0.51). Being
older, not having completed at least primary studies, being on
insulin and having microvascular and/or macrovascular compli-
cations, in both models, signiﬁcantly decreased (p < 0.05)
HRQoL. Additionally, in the patient regression model being
female also lead to signiﬁcantly lower (p < 0.05) patient reported
HRQoL differences. CONCLUSIONS: Pain/discomfort was
reported as the dimension with the most problems for patients
with Type 2 diabetes in Spain Patients’ and physicians’ percep-
tion about diabetic patients HRQoL tended to have good agree-
ment. Results suggest, in the absence of direct patient assessment,
a proxy version of the EQ-5D administered to primary care
physicians can provide a reasonable assessment of the HRQoL
of their patients with type 2 diabetes.
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OBJECTIVES: Intensive treatment to achieve targeted glycemic
index (HbA1c < 7% and FBG < 140 mg %) with the help of early
initiation of basal insulin in addition to oral hypoglycemic agents
has been proposed for Type 2 Diabetes mellitus. Insulin glargine
has been reported to be as efﬁcacious as NPH insulin along with
oral hypoglycemic agents in type 2 Diabetes mellitus. However,
its impact on quality of life has not been evaluated. METHODS:
Forty patients of type 2 diabetes mellitus on two or more oral
hypoglycemic agents for more than three months and unable to
achieve targeted glycemic index were enrolled and randomized
in a open label comparative trial into two groups, 20 patients
each, taking either insulin glargine or NPH insulin in combina-
tion to previous treatment. The end points evaluated were
glycemic index, hypoglycemic episodes impact on treatment sat-
isfaction, Well being and Quality of life. RESULTS: Both the
treatment groups equally achieved euglycemic levels. The mean
decrease in HbA1c level in both groups was same but more
number of patients (15 vs. 10) were able to achieve fair to good
glycemic control in insulin glargine group. Total episodes of
hypoglycemia were 50% lesser in Insulin glargine group (13 vs.
26) with no severe and lesser nocturnal episodes. Quality of life
parameters improved in both groups but signiﬁcantly higher in
insulin glargine group (Treatment satisfaction: 43.75 ± 2.05 vs.
34.44 ± 1.68; General well being: 27.1 ± 2.37 vs. 16.75 ± 1.58;
Total satisfaction: 35.50 ± 2.25 vs. 23.81 ± 1.92). Higher number
of people had overall good to excellent rating of quality of life
(18 vs.10).CONCLUSIONS: Achievement of target glycemic
control was similar in both insulin regimens however, patients
on insulin glargine had signiﬁcantly lesser number of hypo-
glycemic episodes and far better treatment satisfaction, sense of
well being and quality of life.
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OBJECTIVE: This pilot study aimed to collect health utility and
qualitative data from diabetic retinopathy (DR) patients and
members of general public regarding the impact of DR and
varying degrees of vision loss. This data was used to help develop
